License Revenue (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
License Revenue (Details) [Line Items]
Upfront license Payment							$ 6.0
Milestone license payments				$ 6.0			$ 14.0
Net of withholding taxes and other fees and royalties				$ 4.5
Description of licensing agreement					It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
License revenue		$ 1.0	$ 1.0		$ 2.1	$ 1.5
Forecast [Member]
License Revenue (Details) [Line Items]
Milestone license payments	$ 6.0
Net of withholding taxes and other fees and royalties	$ 4.5
South Korea agreement [Member]
License Revenue (Details) [Line Items]
Deferred revenue		$ 3.1			$ 3.1